Patient characteristics (n = 12)
| . | n (%) . |
|---|---|
| Median age (range), y | 64 (53-76) |
| Female | 7 (58%) |
| High-risk cytogenetics | 6 (50%) |
| Median prior lines of therapy (range) | 3 (1-7) |
| Prior proteasome inhibitor | 12 (100%) |
| Prior carfilzomib | 6 (50%) |
| Prior IMiD | 12 (100%) |
| Prior pomalidomide | 2 (17%) |
| Double refractory (to PI and IMiD) | 7 (58%) |
| Prior high-dose melphalan with stem cell rescue | 9 (75%) |
| . | n (%) . |
|---|---|
| Median age (range), y | 64 (53-76) |
| Female | 7 (58%) |
| High-risk cytogenetics | 6 (50%) |
| Median prior lines of therapy (range) | 3 (1-7) |
| Prior proteasome inhibitor | 12 (100%) |
| Prior carfilzomib | 6 (50%) |
| Prior IMiD | 12 (100%) |
| Prior pomalidomide | 2 (17%) |
| Double refractory (to PI and IMiD) | 7 (58%) |
| Prior high-dose melphalan with stem cell rescue | 9 (75%) |
IMiD, immunomodulatory drug; PI, proteasome inhibitor.